Lundbeck and Contera collaborate on RNA-targeting medicines

CNS specialist Lundbeck (LUND: CO) and fellow Denmark based Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines for patients living with serious neurological conditions, where significant unmet medical needs remain.

Together, the companies will explore novel RNA-targeting treatment approaches designed to deliver transformative benefits for patients worldwide. The partnership will leverage Lundbeck's more than 70 years of neuroscience experience and Contera Pharma’s oligonucleotide expertise and pioneering proprietary RNA discovery platforms, including AttackPoint discovery, OligoDisc, and SpliceMatrix.

Contera Pharma will receive an undisclosed upfront payment and full research funding for each target. The company will also be eligible for milestone payments tied to pre-clinical, clinical, regulatory, and commercial achievements, along with tiered royalties on future net sales of any resulting products.